** Shares of medtech co ZimVie ZIMV.O fall ~9.9% to $7.60
premarket
** Needham initiates stock coverage with "hold" rating
** "ZIMV's valuation reflects a struggling spine business
with no near-term path to return to market growth" - Needham
** Brokerage says that selling co's spine business could
result in meaningful upside to shareholder value
** 1 of 2 brokerages rate the stock "hold" and 1 "sell"
or lower; their median PT is $10.50 - LSEG data
** Up to last close, stock down 9.7% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))